The immunological targeting of cold tumors still remains a challenge. Cytokine therapy is promising but has modest efficacy and significant toxicity.

Work at Sonata Therapeutics Inc. has led to the creation of phospholipid hydroperoxide glutathione peroxidase, mitochondrial (PHGPx; GPX4) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.